170 related articles for article (PubMed ID: 31099617)
21. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
Marcucci G; Haferlach T; Döhner H
J Clin Oncol; 2011 Feb; 29(5):475-86. PubMed ID: 21220609
[TBL] [Abstract][Full Text] [Related]
22. Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.
Ali A; Gale RE; Shakoori AR
J Cell Biochem; 2017 May; 118(5):1174-1181. PubMed ID: 27735988
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
24. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
25. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.
Shallis RM; Pollyea DA; Zeidan AM
Blood Rev; 2021 Jul; 48():100806. PubMed ID: 33531169
[TBL] [Abstract][Full Text] [Related]
26. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
27. Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
Percival ME; Estey E
Clin Adv Hematol Oncol; 2017 Aug; 15(8):632-642. PubMed ID: 28949951
[TBL] [Abstract][Full Text] [Related]
28. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
29. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.
Prassek VV; Rothenberg-Thurley M; Sauerland MC; Herold T; Janke H; Ksienzyk B; Konstandin NP; Goerlich D; Krug U; Faldum A; Berdel WE; Wörmann B; Braess J; Schneider S; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Metzeler KH
Haematologica; 2018 Nov; 103(11):1853-1861. PubMed ID: 29903761
[TBL] [Abstract][Full Text] [Related]
30. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
Kadia TM; Ravandi F; Cortes J; Kantarjian H
JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
[TBL] [Abstract][Full Text] [Related]
31. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
Buccisano F; Maurillo L; Del Principe MI; Di Veroli A; De Bellis E; Biagi A; Zizzari A; Rossi V; Rapisarda V; Amadori S; Voso MT; Lo-Coco F; Arcese W; Venditti A
Expert Rev Hematol; 2018 Apr; 11(4):307-313. PubMed ID: 29495904
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
34. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
35. Novel Treatment Paradigms in Acute Myeloid Leukemia.
Khanal N; Upadhyay Banskota S; Bhatt VR
Clin Pharmacol Ther; 2020 Sep; 108(3):506-514. PubMed ID: 32572947
[TBL] [Abstract][Full Text] [Related]
36. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
37. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
38. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
39. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
40. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
